Apheresis, administration of agent, or combination thereof
AssigneeMedtronic, Inc.
InventorsDeepak R. Thakker, Lisa L. Shafer
Life of this patent
Estimating the term…
Abstract
A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation.
Claims19
A method comprising:
- withdrawing fluid from a first cerebrospinal fluid compartment of a subject;
- passing the withdrawn fluid through a reservoir of a medical device to remove the target molecule from the withdrawn fluid, wherein the reservoir contains a medium comprising a solid support to which an antibody directed to the target molecule is bound and wherein the media is capable of removing the target molecule from the cerebrospinal fluid;
- adding a therapeutic agent to the withdrawn fluid with removed target molecule;
- and
- delivering the withdrawn fluid with removed target molecule and added therapeutic agent to a second cerebrospinal fluid compartment of the subject,
- wherein the first and second cerebrospinal fluid compartments are the same or different.
A method for treating a disease associated with amyloid beta accumulation in a subject in need thereof, comprising:
- delivering directly to the central nervous system of the subject a therapeutic agent selected from the group consisting of an ApoE-modulating agent;
- a RAGE inhibitor;
- a β-secretase 1 (BACE1) inhibitor;
- a γ-secretase inhibitor;
- a muscarinic receptor subtype 1 (M1) agonist;
- a growth factor;
- an enzyme capable of degrading amyloid beta;
- a mitochondrial antioxidant;
- insulin;
- and an inhibitor of tumor necrosis factor (TNF).
Dependencies are inferred from the claim text.